Story of Bioculture Group
Bioculture was founded by Mary-Ann and Owen Griffiths with a belief that medical research and biodiversity protection must advance together. Established in Mauritius, the company pioneered ethical, purpose-bred non-human primate (NHP) programs at a time when global standards were still emerging.
Over time, Bioculture evolved from a single breeding operation into a vertically integrated life sciences group, expanding into the United States and into preclinical and translational research.
2025
Launch of ANEWCRO
2024
Investment in Franklin Biolabs
2023 onwards
Strategic growth focused on diversifying across the biomedical value chain with expansion in research services
2019 – 2020
Uptick in demand, coupled with sudden end of supply from China opens fast growth opportunity – Workforce in Mauritius increases fivefold
2009 – 2018
Downward trend for industry following Global Economic Crisis. Company focused on cost management and strengthening efficiency in operations
2012
Set up of BCUS – site in Florida with CDC approved quarantine, and holding of animals for clients
2009
End of exclusivity with CRL, Bioculture now interfaces directly with pharma companies
2006
IAMS (in house data management tool) rolled out AAALAC Accreditation
1990 – 2009
Steady growth with a focus on building robust operations to deliver the gold standard in NHP models for Biomedical Research
1999
BCM becomes ISO 9001 certified
1991
Noveprim (now part of CRL) becomes BCM’s first competitor for supply of MCMs
1992
SPF status of MCMs confirmed in a scientific publication where Bioculture’s owners are listed as co-authors. Discovery happens in 1989 through research supported by Bioculture
1989
Long term exclusivity contract signed with Charles River Laboratories
1985
Bioculture (Mauritius) Ltd founded, pioneering supply of MCMs for Biomedical research
